12^th Asian Biologics and Biosimilars Congress

Uptake and acceptance of biosimilar medicines in the UK is accelerating and will continue to do so as the NHS (National Health Service) has recently introduced a new commissioning framework for biologic and biosimilar medicines. But there is still work to do to optimize the potential cost-saving bene ts of biosimilar throughout the NHS. This presentation describes how unique challenges in the UK to the delivery of biosimilar clinical trials have been identi ed and overcome. It demonstrates how our biosimilar research delivery strategy was put into practice and will use case study examples and project outputs to illustrate the results. Finally, it will showcase the UK’s ongoing campaign which continues to drive changes in attitudes, appetite and acceptance for biosimilars in the UK National Health Service.